Sugi Predict

Sugi Predict / Targets / ROCK1

ROCK1

Rho-associated protein kinase 1 · Q13464 · ROCK1 on Sugi Atlas →

276,557 patent compounds predicted against ROCK1, 153,956 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Ripasudil Ripasudil (SCHEMBL31542) 1.00 12/20
SCHEMBL31541 SCHEMBL31541 0.70 12/20
SCHEMBL91397 SCHEMBL91397 0.62 12/20
SCHEMBL38093 SCHEMBL38093 0.35 12/20
SCHEMBL91529 SCHEMBL91529 0.70 9/20
SCHEMBL77629 SCHEMBL77629 0.68 9/20
Fasudil Fasudil (SCHEMBL4674) 1.00 8/20
SCHEMBL44050 SCHEMBL44050 0.42 8/20
SCHEMBL38289 SCHEMBL38289 0.40 6/20
SCHEMBL98798 SCHEMBL98798 0.63 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL70622) 0.49 5/20
SCHEMBL84515 SCHEMBL84515 0.45 5/20
SCHEMBL92545 SCHEMBL92545 0.41 5/20
SCHEMBL37536 SCHEMBL37536 0.36 5/20
Linifanib Linifanib (SCHEMBL93804) 1.00 4/20
SCHEMBL77442 SCHEMBL77442 0.61 4/20
SCHEMBL98881 SCHEMBL98881 0.57 4/20
SCHEMBL99955 SCHEMBL99955 0.53 4/20
SCHEMBL99400 SCHEMBL99400 0.52 4/20
SCHEMBL49220 SCHEMBL49220 0.51 4/20

Clinical trials — most relevant to ROCK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension PHASE4RECRUITING
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human PHASE4UNKNOWN
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction PHASE4UNKNOWN
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer PHASE2RECRUITING
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula PHASE2COMPLETED
Simvastatin in Secondary Progressive Multiple Sclerosis PHASE2COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention PHASE2NOT_YET_RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction EARLY_PHASE1RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
The Continuous Positive Airway Pressure Effect on Rho-associated Coiled-coil Containing Kinases Activity. nanUNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Glucagon Like Peptide-1 in Remote Ischemic Conditioning nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Inhaled Nitric Oxide (iNO) in Post-Pulmonary Embolism (Post-PE) nanCOMPLETED
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F nanACTIVE_NOT_RECRUITING
The Activation of Hippo Pathway in Nasal Polyps nanUNKNOWN
Evaluation of the Level and Prognostic Relevance of New Neuroinflammation Markers in Subarachnoid Haemorrhage nanCOMPLETED
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? nanUNKNOWN
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF nanRECRUITING
Screening and Identification of Biomarkers for High Myopia by a Rapid Method nanUNKNOWN
Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke nanCOMPLETED
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ROCK1 binder may also engage these)

ProteinNameSimilarity
O77819 — 1.000 O77819 →
Q28021 — 1.000 Q28021 →
Q62868 — 1.000 Q62868 →
P70335 — 1.000 P70335 →
M3TYT0 — 1.000 M3TYT0 →
Q63644 — 1.000 Q63644 →
P70336 — 1.000 P70336 →
ROCK2 Rho-associated protein kinase 2 1.000 landscape →
CDC42BPA Serine/threonine-protein kinase MRCK alpha 0.996 landscape →
O54874 — 0.995 O54874 →
CDC42BPB Serine/threonine-protein kinase MRCK beta 0.992 landscape →
Q3UU96 — 0.990 Q3UU96 →
Q7TT50 — 0.990 Q7TT50 →
A8WVU9 — 0.990 A8WVU9 →
O15078 — 0.990 O15078 →
Q5ZKK5 — 0.989 Q5ZKK5 →
P85120 — 0.989 P85120 →
Q6A078 — 0.989 Q6A078 →
P85001 — 0.989 P85001 →
Q5BJF6 — 0.988 Q5BJF6 →
P92199 — 0.987 P92199 →
Q9W1B0 — 0.987 Q9W1B0 →
Q7TT49 — 0.987 Q7TT49 →
Q9UJC3 — 0.987 Q9UJC3 →
A7MD70 — 0.987 A7MD70 →
P28738 — 0.987 P28738 →
Q8MIT6 — 0.987 Q8MIT6 →
Q6NRC9 — 0.986 Q6NRC9 →
A1Z8P9 — 0.986 A1Z8P9 →
Q6ZU80 — 0.986 Q6ZU80 →